Brief: DiaMedica Therapeutics Says FDA Maintaining Clinical Hold On Remedy2 Trial
26/10/2022 23:31
Oct 26 (Reuters) - DiaMedica Therapeutics Inc DMAC.O :
* DIAMEDICA THERAPEUTICS PROVIDES UPDATE ON REMEDY2 TRIAL
* DIAMEDICA THERAPEUTICS INC - FDA STATED IT IS MAINTAINING
ITS
CLINICAL HOLD AT THIS TIME
* DIAMEDICA THERAPEUTICS INC - ADDITIONAL NON-CLINICAL DATA
ABOUT
MATERIALS USED BY A HOSPITAL IN IV INFUSION PROCESS NEEDED TO
RESOLVE CLINICAL HOLD
* DIAMEDICA THERAPEUTICS INC - CO WILL REQUEST A TYPE A FDA
MEETING TO CONFIRM STUDY DESIGN AND OBTAIN ADDITIONAL GUIDANCE
TOWARDS LIFTING CLINICAL HOLD
Source text for Eikon: ID:nBwbV0w82a
Further company coverage: DMAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program